Close Menu

This article has been updated with comments from Roche's earnings call.

NEW YORK – Roche today reported flat half-year revenues for its Diagnostics division. At constant exchange rates, diagnostics revenues were up 2 percent, primarily due to the immunodiagnostics business as well as to overall growth in the second quarter.

For the first half of 2019, the Roche Group reported CHF 30.47 billion ($30.86 billion) in total sales, up 8 percent (9 percent at constant exchange rates) from CHF 28.11 billion during the first half of 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.